Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Please login or register to access this content




This site is intended to support the scientific exchange of information by providing health care professionals (HCPs) with access to unedited, unmodified, and unaltered select material from educational sessions and science sessions as presented at ASH 2021 Annual Meeting.

Novartis assumes no responsibility for the content contained on the site. Additionally, the material may contain information about compounds that are either investigational or being studied for new uses, and for which efficacy and safety have not been established. There is no guarantee that any compound will become commercially available for the uses under investigation.

While your access to the ASH video collection via Springer Healthcare is provided at no cost to you, a $6.18 USD transfer of value per video shall be reported by Novartis to meet its legally required reporting obligations.

Please note that HCPs are limited to a total of 3 educational items per year from Novartis. Take this into consideration when selecting which videos to view.

Please note that you should not access this site if you are a:

  • HCP licensed in Minnesota;
  • Member of state, federal, or D.C. formulary committees;
  • Employee of federal, state, or county entities (including state universities or county/state/federal hospitals);
  • HCP employed by or affiliated with institutions that restrict interactions with the biopharmaceutical industry;
  • Medical student pursuing a medical degree in California (e.g., MD, DO)

By clicking Register, you affirm that your licensure and/or professional affiliations do not prohibit you from accessing an educational video from the ASH 2021 Annual Meeting being made available by Novartis Oncology.




Related Content – MPN/GvHD
No related content found

Accessing this content will consume 1 of your  3 remaining content items.  

Are you sure you wish to proceed?

To access this collection, please read through and accept any terms and conditions and confirm that you are a healthcare professional.

By accessing this collection you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.

  • Residents of the United States will need to provide a full validated registration
  • Residents of the United States will have their use of the content tracked and reported for Transfer of Value (ToV) reporting purposes 
  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorized duplication or unauthorized distribution of the materials
  • You accept Springer Healthcare’s Privacy Policy
© 2022 American Society of Hematology. All rights reserved. ASH® and the ASH logo are registered trademarks of the American Society of Hematology. Used with permission.
This web site is provided for informational purposes and personal use only, and is not intended to provide medical advice, diagnosis, or treatment or for commercial use. The ideas and opinions expressed herein do not necessarily reflect those of the American Society of Hematology (ASH®). The mention of any product, service or therapy in this collection of materials should not be construed as an endorsement of the products mentioned.